Immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes: downregulation of multiple proapoptotic factors.

We previously reported the cellular, functional and cytogenetic characterization of immunoresistant (IR) 13-06-IR29 and 13-06-IR30 human glioma cell clones isolated after immunoselection with alloreactive cytotoxic T lymphocytes (aCTL). Relative to the 13-06-MG parental cells, both clones resisted aCTL lysis at multiple effector to target ratios; the resistant phenotype was maintained for 13-41 cell doublings after cloning and when selective pressure was removed; cross-resistance to other inducers of apoptosis/cell death was also observed (Gomez et al, 2006; Gomez and Kruse, 2007). In this study we further characterize the IR clones for factors that may contribute to the resistance. Data obtained by in-vitro quantitative morphologic and 7-amino actinomycin D flow cytometric assays revealed reduced apoptotic cell death when IR clones were coincubated with aCTL, relative to the parental cells. Since changes in apoptosis were observed, we examined the expression patterns of apoptosis-related genes in several extracts of parental cells and IR clones using pathway-specific cDNA microarray analysis. In general, the apoptotic factors were downregulated in the IR clones. From three separate extracts analyzed separately on microarrays, three factors, ATM, caspases 3 and 8, were statistically downregulated in both IR clones. Immunoblotting of the proteins confirmed the findings. Therefore, a possible mechanism for immunoresistance in gliomas may be achieved by the downregulation of one or more genes in the apoptotic pathway.

[1]  V. Preedy,et al.  European Organization for Research and Treatment of Cancer , 2010 .

[2]  C. Kruse,et al.  Cellular and Functional Characterization of Immunoresistant Human Glioma Cell Clones Selected With Alloreactive Cytotoxic T Lymphocytes Reveals Their Up-regulated Synthesis of Biologically Active TGF-β , 2007, Journal of immunotherapy.

[3]  M. Varella‐Garcia,et al.  Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization. , 2006, Cancer genetics and cytogenetics.

[4]  B. Nolan.  Radiotherapy Plus Concomitant and Adjuvant Temozolomide for GlioblastomaStupp R, for the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group (Centre Hospitalier Universitaire Vaudois, Lausann , 2006 .

[5]  C. Kruse,et al.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression. , 2006, Gene therapy & molecular biology.

[6]  Robert Tibshirani,et al.  A simple method for assessing sample sizes in microarray experiments , 2006, BMC Bioinformatics.

[7]  L. Ricci-Vitiani,et al.  Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. , 2005, Cancer research.

[8]  D. Bellgrau,et al.  Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors , 2005, Journal of Neuro-Oncology.

[9]  D. Bellgrau,et al.  Allogeneic tumor-specific cytotoxic T lymphocytes , 2005, Cancer Immunology, Immunotherapy.

[10]  L. Gerschenson,et al.  Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors. , 2004, Neuro-oncology.

[11]  D. Elashoff,et al.  Allelic Imbalance of 12q22–23 Associated with APAF-1 Locus Correlates with Poor Disease Outcome in Cutaneous Melanoma , 2004, Cancer Research.

[12]  M. Varia,et al.  Pilot Study of Local Autologous Tumor Infiltrating Lymphocytes for the Treatment of Recurrent Malignant Gliomas , 2004, Journal of Neuro-Oncology.

[13]  O. Tachibana,et al.  Frequent LOH at Chromosome 12q22‐23 and Apaf‐1 Inactivation in Glioblastoma , 2003, Brain pathology.

[14]  D. B. Paul,et al.  Human Alloreactive CTL Interactions with Gliomas and with Those Having Upregulated HLA Expression from Exogenous IFN-γ or IFN-γ Gene Modification , 2003 .

[15]  D. B. Paul,et al.  Human alloreactive CTL interactions with gliomas and with those having upregulated HLA expression from exogenous IFN-gamma or IFN-gamma gene modification. , 2003, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[16]  G. Cohen,et al.  The Apaf-1 apoptosome: a large caspase-activating complex. , 2002, Biochimie.

[17]  C. Kruse,et al.  Strategies using the immune system for therapy of brain tumors. , 2001, Hematology/oncology clinics of North America.

[18]  K. Khanna,et al.  ATM, a central controller of cellular responses to DNA damage , 2001, Cell Death and Differentiation.

[19]  S. Fulda,et al.  Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer , 2001, Oncogene.

[20]  S. Tribius,et al.  ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture. , 2001, International journal of radiation oncology, biology, physics.

[21]  K. Helin,et al.  Apaf-1 is a transcriptional target for E2F and p53 , 2001, Nature Cell Biology.

[22]  R. Jackson,et al.  Protein Factor Requirements of the Apaf-1 Internal Ribosome Entry Segment: Roles of Polypyrimidine Tract Binding Protein and upstream of N-ras , 2001, Molecular and Cellular Biology.

[23]  Darell D. Bigner,et al.  Brain Tumor Immunotherapy , 2000, Humana Press.

[24]  Carol A. Kruse,et al.  Cytotoxic T-Lymphocytes Reactive to Patient Major Histocompatibility Complex Proteins for Therapy of Brain Tumors , 2001 .

[25]  R. Schreiber,et al.  Eradication of established tumors by CD8+ T cell adoptive immunotherapy. , 2000, Immunity.

[26]  T. Ley,et al.  DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. , 2000, Immunity.

[27]  G. Barnett,et al.  T cell adoptive immunotherapy of newly diagnosed gliomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  B. Vikram,et al.  Antisense ATM gene therapy: a strategy to increase the radiosensitivity of human tumors , 2000, Gene Therapy.

[29]  M. MacFarlane,et al.  Initiation of Apaf-1 translation by internal ribosome entry , 2000, Oncogene.

[30]  T. Mak,et al.  Apaf1 Is Required for Mitochondrial Pathways of Apoptosis and Brain Development , 1998, Cell.

[31]  Michael B. Cohen.  Advances in Neuro-oncology II , 1998, Neurology.

[32]  J. Stears,et al.  Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2 , 1997, Cancer Immunology, Immunotherapy.

[33]  Xiaodong Wang,et al.  Apaf-1, a Human Protein Homologous to C. elegans CED-4, Participates in Cytochrome c–Dependent Activation of Caspase-3 , 1997, Cell.

[34]  C. Kruse,et al.  Artificial‐capillary‐systemdevelopment of human alloreactive cytotoxic T‐lymphocytes that lyse brain tumour , 1997 .

[35]  P. Walker,et al.  Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. , 1997, Journal of immunology.

[36]  C. Kruse,et al.  Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours. , 1997, Biotechnology and applied biochemistry.

[37]  D. Mercola,et al.  Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. Gritzapis,et al.  Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine‐activated killer cell function in patients with breast cancer , 1993, Cancer.

[39]  L. Watkins,et al.  A 9L Gliosarcoma Transplantation Model for Studying Adoptive Immunotherapy into the Brains of Conscious Rats , 1992, Cell transplantation.

[40]  D. Bellgrau,et al.  Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[41]  W. Hickey,et al.  Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement. , 1986, Journal of immunology.

[42]  A. Zwaveling.  [Patients with breast cancer: current therapy]. , 1978, Tijdschrift voor ziekenverpleging.